DNA
Ginkgo Bioworks Holdings, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$11.21Close
$652.5MMarket cap
$5.48 – $14.9852-week range
Nov 5, 2026Next report
Highlights
Cautions
- Trend not confirmed 7 of 8 conditions · over 25% off the high
- Far from its high 25% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
25%
1wk
up 12.2%
price change
1mo
down 12.6%
price change
12-month return
down 7%
market up 11% ·
its own down 19%
F-score
—
— Not assessed
Altman Z
-7.42
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.3×
price / book
Earnings yield
down 65.0%
EBIT / enterprise value
Cheaper than
30%
of the market · expensive
Revenue growth
down 25%
year on year
EPS growth
—
latest quarter
Sales growth
down 48%
latest quarter · +1 pts
ROE
0%
return on equity
Free cash margin
down 105%
-$178.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
11.8%
$1.32 a day · 2×ATR $8.57
RS
73 / 99
vs the universe
Trend
7 / 8
over 25% off the high
Relative volume
1.1×
vs 50-day average
Up/down volume
0.94
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 7 of 8
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 7.1% over the year, from 54m to 58m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 25.1% over the year, from $227.0M to $170.2M.
Last reported
Aug 5, 2026
Last shock
Oct 6, 2026-17% in one session6.9× volumeno filing matched-10% since
Financials
- Net -0%
- Free cash -105%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $76.7M | $313.8M | $477.7M | $251.5M | $227.0M | $170.2M |
| Operating income | -$137.0M | -$1.8B | -$2.2B | -$864.4M | -$559.8M | -$315.3M |
| Net income | -$126.6M | -$1.8M | -$2.1M | -$893,000 | -$547,000 | -$313,000 |
| Net margin | -165% | -1% | -0% | -0% | -0% | -0% |
| Earnings per share | -$3.97 | -$0.05 | -$0.05 | -$0.02 | -$0.01 | -$0.01 |
| Free cash flow | -$193.7M | -$310.3M | -$304.5M | -$336.3M | -$382.1M | -$178.7M |
| Free cash margin | -253% | -99% | -64% | -134% | -168% | -105% |
| Cash | $380.8M | $1.6B | $1.3B | $944.1M | $561.6M | $167.2M |
| Shareholders' equity | $461.4M | $1.5B | $1.7B | $1.1B | $716.1M | $508.6M |
| Shares outstanding | 32.21m | 40.28m | 47.30m | 50.03m | 54.37m | 58.21m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 30, 2026 | Regulation FD ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 7, 2026 | Acquisition or disposal ↗ |
| Feb 27, 2026 | Material agreement ↗ |
| Feb 26, 2026 | Results ↗ |
| Dec 23, 2025 | Director or officer change · Other events ↗ |
| Nov 6, 2025 | Results ↗ |
| Sep 4, 2025 | Material agreement ↗ |
| Aug 29, 2025 | Other events ↗ |